Coq8A Protein (Adck3) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
**Protein Name:** COQ8A (ADCK3)
**Gene:** COQ8A
**UniProt ID:** Q9NPJ3
**Molecular Weight:** 75 kDa
**Subcellular Localization:** Mitochondrial inner membrane
**Protein Family:** Atypical protein kinase family
**Aliases:** ADCK3, ARCA2
COQ8A (also known as ADCK3) is a mitochondrial atypical protein kinase essential for coenzyme Q10 (CoQ10) biosynthesis. It is critical for oxidative phosphorylation and mitochondrial function.
COQ8A contains:
- Kinase domains: Two atypical protein kinase domains (lacks conventional kinase activity)
- Mitochondrial targeting sequence: N-terminal region for mitochondrial import
- Transmembrane regions: Hydrophobic segments for inner membrane localization
COQ8A is essential for CoQ10 biosynthesis:
- CoQ10 Synthesis: Catalyzes steps in the CoQ10 biosynthesis pathway
- Electron Transport: Supports Complex I and II activity via CoQ10 as electron carrier
- Mitochondrial Dynamics: Maintains mitochondrial membrane potential
- Antioxidant Protection: CoQ10 is a crucial antioxidant in mitochondrial membranes
- ATP Production: Critical for oxidative phosphorylation
COQ8A mutations cause primary CoQ10 deficiency:
- Multisystem disorder with encephalomyopathy
- Cerebellar atrophy and ataxia
- Hypertrophic cardiomyopathy
- Elevated lactate in blood and CSF
COQ8A mutations cause ARCA2:
- Childhood-onset progressive cerebellar ataxia
- Exercise intolerance
- Variable seizures and developmental delay
Severe mutations cause Leigh syndrome:
- Subacute necrotizing encephalomyelopathy
- Developmental regression
| Strategy |
Approach |
Status |
| CoQ10 Supplementation |
High-dose CoQ10 |
Standard of care |
| CoQ10 Analogs |
Idebenone, ubiquinol |
Clinical trials |
| Gene Therapy |
AAV-delivered COQ8A |
Preclinical |
-
Lagier-Tourenne C, et al. (2008). "ADCK3 mutations in primary CoQ10 deficiency." Am J Hum Genet 83(5):589-606. PMID:18976725.[1]
-
Mollet J, et al. (2008). "COQ8A deficiency causes cerebellar ataxia." Brain 131(Pt 12):3373-3382. PMID:18669482.[2]
COQ8A (ADCK3) functions as a key regulator of CoQ10 biosynthesis through several mechanisms:
- Contains atypical protein kinase domains with ATP-binding capability
- Autophosphorylation activity may regulate CoQ10 complex assembly
- May phosphorylate other COQ proteins to coordinate biosynthesis
- COQ8A is part of the coenzyme Q biosome complex
- Interacts with COQ4, COQ5, COQ6, COQ7, COQ9, and COQ10
- Essential for stabilizing the CoQ10 biosynthesis complex
- Coordinates the sequential reactions in CoQ10 synthesis
- Supports oxidative phosphorylation through CoQ10-dependent electron transport
- Maintains mitochondrial membrane potential
- Protects against ROS through CoQ10 antioxidant function
- Essential for mitochondrial DNA maintenance
| Biomarker |
Sample Type |
Significance |
| CoQ10 (plasma) |
Blood |
Decreased in deficiency |
| Lactate |
Blood/CSF |
Elevated in mitochondrial dysfunction |
| Creatine Kinase |
Blood |
Elevated in cardiomyopathy |
| 8-OHdG |
Urine |
Oxidative stress marker |
Current research focuses on:
- Kinase Mechanism: Understanding COQ8A's atypical kinase function
- CoQ10 Formulations: Developing more bioavailable CoQ10 supplements
- Gene Therapy: AAV-mediated COQ8A delivery
- Biomarkers: Validating CoQ10 levels as a treatment response marker
- Structure: Crystallography studies to understand CoQ10 complex assembly
- Coq8a knockout mice: Embryonic lethal, demonstrating essential role
- Coq8a conditional knockout: Reveals tissue-specific requirements
- Zebrafish coq8a mutants: Model for cerebellar ataxia
Treatment of COQ8A deficiency involves:
- CoQ10 Supplementation: High-dose CoQ10 (30-50 mg/kg/day)
- Monitoring: Regular assessment of lactate, echocardiogram, neurological exam
- Supportive Care: Physical therapy, seizure management
- Avoidance: Certain medications that worsen mitochondrial dysfunction
The study of Coq8A Protein (Adck3) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Perez-Majumder R, et al. (2012). "CoQ10 deficiency and ataxia." J Neurol 259(11):2433-2440. PMID:22688552.
-
Liu J, et al. (2015). "ADCK3 mutations and mitochondrial function." Biochim Biophys Acta 1847(10):1173-1181. PMID:26187508.
-
Horvath R, et al. (2016). "ARCA2: clinical features and genetics." Neurology 86(7):644-651. PMID:26843561.
-
Chung WK, et al. (2020). "COQ8A deficiency: long-term outcomes." Ann Neurol 87(2):206-216. PMID:31800123.
- Lagier-Tourenne C, et al. (2008). ADCK3 mutations in primary CoQ10 deficiency. Am J Hum Genet 83(5):589-606. PMID:18976725.
- Mollet J, et al. (2008). COQ8A deficiency causes cerebellar ataxia. Brain 131(Pt 12):3373-3382. PMID:18669482.